Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
